GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

COSCIENS Biopharma CSCI.TO · CAD

Health Care · Toronto Stock Exchange · 🇨🇦 Canada

Compare

8.40

-1.18%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$7.5m

FY2016FY2025

Net income

−$10.4m

FY2016FY2025

Free cash flow

−$9.2m

FY2016FY2025

Shareholders' equity

$3.8m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$7.5m$9.6m$7.1m$5.6m$5.3m$3.7m$500,000$26.9m$900,000$900,000
Research and development$3.0m$8.3m$2.0m$12.5m$6.6m$1.5m$1.8m$2.9m$10.6m$16.4m
Operating income−$10.4m−$14.0m−$4.6m−$15.2m−$8.7m−$6.1m−$9.5m$9.8m−$23.1m−$29.5m
Net income−$10.4m−$15.3m−$3.5m−$22.7m−$8.4m−$5.1m−$6.0m$4.2m−$16.8m−$25.0m
Diluted earnings per share-3.27-5.93-1.89-4.63-1.82-3.18-8.576.00-28.00-62.50

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$21.4m$35.1m$23.7m$56.0m$80.1m$37.0m$20.0m$25.0m$22.2m$31.7m
Cash and short-term investments$7.3m$16.4m$6.7m$50.6m$65.3m$24.3m$7.8m$14.5m$7.8m$22.0m
Total liabilities$17.6m$21.9m$2.7m$20.3m$27.1m$23.8m$22.4m$23.1m$25.0m$25.4m
Debt$2.1m$2.3m$1.7m$200,000$200,000$200,000$900,000———
Shareholders' equity$3.8m$13.2m$21.0m$35.8m$53.0m$13.2m−$2.5m$1.9m−$2.8m$6.2m
Shares outstanding3m3m2m5m5m2m1m1m1m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$8.5m−$14.6m−$2.6m−$13.7m−$8.6m−$4.1m−$10.7m$6.8m−$22.9m−$29.0m
Capital spending−$706,000−$1.2m−$722,000−$10,000−$640,000——−$10,000—−$70,000
Free cash flow−$9.2m−$15.7m−$3.3m−$13.7m−$9.2m−$4.1m−$10.7m$6.8m−$22.9m−$29.1m

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Revenue$1.8m$1.5m$2.7m$1.5m$3.3m$1.9m$2.3m$2.1m
Operating income−$2.4m−$2.0m−$2.4m−$3.6m−$3.6m−$4.8m−$3.8m−$1.8m
Net income−$2.2m−$1.8m−$2.7m−$3.7m−$6.7m−$5.8m−$1.4m−$1.4m
Diluted earnings per share-0.69-0.57-0.85-1.16-2.14-1.85-0.64-0.66
Cash from operations−$1.0m—−$4.0m−$1.0m−$2.0m−$7.0m—−$4.0m
Total assets$21.4m$23.9m$27.6m$31.1m$35.1m$43.8m$50.0m$31.8m
Cash and short-term investments$7.3m$8.5m$9.3m$13.8m$16.4m$20.0m$27.8m$29.5m
Debt$1.9m$2.0m$2.0m$2.0m$2.0m$1.2m$1.3m$80,000
Shareholders' equity$3.8m$5.1m$7.1m$10.1m$13.2m$20.0m$26.2m$13.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.2%15.2%31.1%
Operating income-12.0%11.2%-11.4%
Net income-23.0%15.2%-14.6%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-142.7%-148.2%-152.0%-213.4%
Net margin-150.2%-173.8%-168.3%-232.1%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 4-to-1 reverse split · 3 May 2024
  • 25-to-1 reverse split · 21 Jul 2022
  • 100-to-1 reverse split · 20 Nov 2015
  • 6-to-1 reverse split · 5 Oct 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.